IP Library Granted Patent US 9,932,385
Granted Patent B2
US 9,932,385 · App. 14/776,908 · Granted Apr 3, 2018

Mutant proteins and methods for their production

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,932,385
App. No.
14/776,908
Granted
Apr 3, 2018
Kind
B2
Abstract

The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallization studies and also in screening to identify compounds for use in drug discovery and therapy.

Claims (12)

1. A mutant membrane protein which has increased conformational stability compared to its parent membrane protein, wherein the one or more mutations are located at the interfaces between transmembrane alpha-helices, or in a kinked region or in an alpha-helix adjacent to a kink, wherein the mutant membrane protein is the cocaine-sensitive rat serotonin transporter (SERT) protein which comprises one or more amino acid mutations selected from P499A, A505L, G113A, L99A, G278A, A169L, F311A, G115A, L405A and L406A.

2. The mutant membrane protein according to claim 1 comprising three mutations selected from G278A, A505L, L99A and P499A.

3. The mutant membrane protein according to claim 1 comprising mutations L99A, G278A and A505L.

4. The mutant membrane protein according to claim 1 comprising mutations L405A, P499A and A505L.

5. The mutant membrane protein according to claim 1 which is bound to a ligand.

6. A method of selecting a binding partner of a mutated membrane protein, the method comprising the steps of

a) providing a mutant membrane protein according to claim 1 ,

b) contacting the mutant membrane protein with one or more compounds,

c) determining whether the one or more compounds bind to the mutant membrane protein, and

d) isolating one or more compounds.

7. The method according to claim 6 wherein mutant membrane protein is immobilised onto a solid support.

8. A mutant membrane protein which has increased conformational stability compared to its parent membrane protein, wherein the one or more mutations are located at the interfaces between transmembrane alpha-helices, or in a kinked region or in an alpha-helix adjacent to a kink, comprising at least one or more mutations which are at the corresponding amino acid positions of P499A, A505L, G113A, L99A, G278A, A169L, F311A, G115A, L405A and L406A of SEQ ID NO: 1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2018
From: MEDICAL RESEARCH COUNCIL
To: UNITED KINGDOM RESEARCH AND INNOVATION
Reel/Frame 046469/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2015
From: TATE, CHRISTOPHER GORDON
To: MEDICAL RESEARCH COUNCIL
Reel/Frame 037363/0490 →